Nasus Pharma Ltd. (NSRX) - Net Assets
Based on the latest financial reports, Nasus Pharma Ltd. (NSRX) has net assets worth $2.77 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($5.00 Million) and total liabilities ($2.24 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of Nasus Pharma Ltd. to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $2.77 Million |
| % of Total Assets | 55.32% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Nasus Pharma Ltd. - Net Assets Trend (2022–2025)
This chart illustrates how Nasus Pharma Ltd.'s net assets have evolved over time, based on quarterly financial data. Also explore Nasus Pharma Ltd. (NSRX) total assets for the complete picture of this company's asset base.
Annual Net Assets for Nasus Pharma Ltd. (2022–2025)
The table below shows the annual net assets of Nasus Pharma Ltd. from 2022 to 2025. For live valuation and market cap data, see NSRX stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $2.77 Million | +186.18% |
| 2024-12-31 | $-3.21 Million | +15.41% |
| 2023-12-31 | $-3.80 Million | -36.34% |
| 2022-12-31 | $-2.79 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Nasus Pharma Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 843900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $21.29 Million | 769.08% |
| Total Equity | $2.77 Million | 100.00% |
Nasus Pharma Ltd. Competitors by Market Cap
The table below lists competitors of Nasus Pharma Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
IL&FS Investment Managers Limited
NSE:IVC
|
$27.17 Million |
|
Wulff-Yhtiot Oy
HE:WUF1V
|
$27.17 Million |
|
Shengli Oil & Gas Pipe Holdings Limited
F:GSG
|
$27.18 Million |
|
BBC Co. Ltd.
KQ:318410
|
$27.18 Million |
|
Cohen & Company Inc
NYSE MKT:COHN
|
$27.17 Million |
|
Morphic Ethical Equities Fund Ltd
AU:MEC
|
$27.13 Million |
|
Hyungji Elite
KO:093240
|
$27.12 Million |
|
Birman Wood and Hardware Ltd
TA:BIRM
|
$27.10 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Nasus Pharma Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -3,212,000 to 2,768,000, a change of 5,980,000.
- Net loss of 5,856,000 reduced equity.
- New share issuances of 8,485,000 increased equity.
- Other factors increased equity by 3,351,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-5.86 Million | -211.56% |
| Share Issuances | $8.48 Million | +306.54% |
| Other Changes | $3.35 Million | +121.06% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Nasus Pharma Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 10.23x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | $-0.31 | $3.14 | x |
| 2023-12-31 | $-0.42 | $3.14 | x |
| 2024-12-31 | $-0.35 | $3.14 | x |
| 2025-12-31 | $0.31 | $3.14 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Nasus Pharma Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -211.56%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.81x
- Recent ROE (-211.56%) is below the historical average (-52.89%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.43 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-671.30K |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.21 Million |
| 2025 | -211.56% | 0.00% | 0.00x | 1.81x | $-6.13 Million |
Industry Comparison
This section compares Nasus Pharma Ltd.'s net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $15,722,864,400
- Average return on equity (ROE) among peers: 13.96%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Nasus Pharma Ltd. (NSRX) | $2.77 Million | 0.00% | 0.81x | $27.17 Million |
| AbbVie Inc (ABBV) | $3.94 Billion | 130.39% | 12.45x | $362.53 Billion |
| Amgen Inc (AMGN) | $29.88 Billion | 25.85% | 1.60x | $178.47 Billion |
| Amarin Corporation PLC (AMRN) | $24.15 Million | -158.05% | 0.75x | $303.32 Million |
| AstraZeneca PLC (AZN) | $15.42 Billion | 39.20% | 0.94x | $286.68 Billion |
| Biogen Inc (BIIB) | $6.96 Billion | 19.82% | 0.45x | $27.74 Billion |
| Bristol-Myers Squibb Company (BMY) | $11.85 Billion | 8.50% | 1.83x | $115.20 Billion |
| Gilead Sciences Inc (GILD) | $86.10 Million | -36.35% | 0.19x | $169.10 Billion |
| GlaxoSmithKline PLC ADR (GSK) | $9.65 Billion | 55.84% | 1.65x | $111.15 Billion |
| Johnson & Johnson (JNJ) | $71.15 Billion | 21.66% | 0.88x | $541.18 Billion |
| Eli Lilly and Company (LLY) | $8.27 Billion | 32.73% | 1.30x | $883.43 Billion |
About Nasus Pharma Ltd.
Nasus Pharma Ltd. operates as a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. The company offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency… Read more